Axsome Therapeutics opened lower at $148.07, compared with its previous close of $149.24. In the last trading session, the stock traded between $145.00 and $150.34. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Axsome Therapeutics is now worth
$ 365.68
Giving a profit of
$ 265.68 (265.68%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 18 Analysts
Buy
94.44%
Hold
5.56%
Sell
0%
Markets Today
Today's Change
$-4.73 (-3.17%)
Day High
$150.34
Day Low
$145.00
Day Open
$148.07
Prev Close
$149.24
Volume
8,27,246
1W Return
5.52%
1M Return
-12.96%
3M Return
-33.00%
6M Return
-33.24%
1Y Return
3.51%
Fundamentals
Market Cap ($ Mn)
7,601
PE Ratio
-
PB Ratio
124.95
PEG Ratio
-
ROE
-265.23%
ROCE
-55.06%
EPS (TTM)
$-0.24
Investment Returns
1 Week
5.52%
1 Month
-12.96%
3 Months
-33.00%
6 Months
-33.24%
9 Months
-22.39%
Financials
Quarterly
All values in $ Mn
150.0
Jun 25
171.0
Sep 25
196.0
Dec 25
191.2
Mar 26
218.4
Jun 26
259.7
Sep 26
Updates
4Nov
UBS maintains Buy on Axsome Therapeutics, cuts price target to $239
UBS maintains a Buy rating on Axsome Therapeutics. Price target lowered from $256 to $239. Analyst Ashwani Verma issued the revised valuation.
9 days ago
3Nov
RBC Capital maintains Outperform on Axsome Therapeutics, cuts target to $273
RBC Capital maintains Outperform rating on Axsome Therapeutics. Price target lowered from $295 to $273 by analyst Leonid Timashev.
9 days ago
3Nov
Guggenheim maintains Buy on Axsome Therapeutics, cuts price target to $250
Guggenheim maintains a Buy rating on Axsome Therapeutics. Price target lowered from $275 to $250 by analyst Yatin Suneja. No change to the overall investment recommendation status.
9 days ago
25Sep
Axsome Therapeutics turns $100 into $2,555 over 10 years
A $100 investment in Axsome Therapeutics 10 years ago is now worth $2,555.80. Average annual return over the decade was 37.87%. Stock outperformed the market by 24.39% on an annualized basis. Current market capitalization stands at $10.27 billion.
1mo ago
21Sep
Axsome survey: 97% say agitation harms Alzheimer's quality of life
97% of caregivers report agitation negatively impacts Alzheimer's patient quality of life. Survey of 751 US adults conducted by Harris Poll with CaringKind input. 76% wish they had recognized agitation symptoms sooner. Results presented at Psych Congress 2026 in New Orleans.
1mo ago
2Sep
Axsome Therapeutics to present at six investor conferences in September
Axsome Therapeutics to participate in six investor conferences in September 2026. Events include fireside chats at Wells Fargo, Cantor, Morgan Stanley, and Baird. Live webcasts available for four sessions; replays accessible for 30 days. Company focuses on CNS disorders including depression, Alzheimer’s, and sleep apnea.
